Welcome, please sign in
Follow DJO on Facebook Follow DJO on Twitter
Grand Rounds
  Most Recent Cases
  Dates of Case
  Type of Case
  Submit a Grand Round.
  Register with DJO to receive personalized updates.

If you're already a
member, please sign in.
47 year old female with history of flashes of light OD
Digital Journal of Ophthalmology 2005
Volume 11, Number 6
January 9, 2005
Printer Friendly



Rishi Singh, M.D. | Massachusetts Eye and Ear Infirmary
Donald D'Amico, M.D. | Massachusetts Eye and Ear Infirmary



References
1. Charteris DG. Sethi CS. Lewis GP. Fisher SK. Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye. 2002; 16(4):369-74.
2. The Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983; 90: 121-125.
3. Cardillo JA. Stout JT. LaBree L. Azen SP. Omphroy L. Cui JZ. Kimura H. Hinton DR. Ryan SJ. Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 1997; 104(7):1166-73.
4. Claes C, Bartz-Schmidt K, Eckardt C. Advanced Vitreoretinal Course, Antwerp, Belgium Mar. 16-8 2001.
5. Kon CH. Asaria RH. Occleston NL. Khaw PT. Aylward GW. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. British Journal of Ophthalmology. 2000; 84(5):506-1.
6. Bonnet M. Guenoun S. Surgical risk factors for severe postoperative proliferative vitreoretinopathy (PVR) in retinal detachment with grade B PVR. Graefes Archive for Clinical & Experimental Ophthalmology. 1995; 233(12):789-91.
7. Nagasaki H. Shinagawa K. Mochizuki M. Risk factors for proliferative vitreoretinopathy. Progress in Retinal & Eye Research. 1998; 17(1):77-98.
8. Abrams GW. Azen SP. McCuen BW 2nd. Flynn HW Jr. Lai MY. Ryan SJ. Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11. Archives of Ophthalmology. 1997; 115(3):335-44.
9, Lewis H, Aaberg TM, Abrams GW. Cause of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol 1991; 111: 8-14.
10. Wiedemann P. Hilgers RD. Bauer P. Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. American Journal of Ophthalmology. Oct; 126(4):550-9.
11. Asaria RH. Kon CH. Bunce C. Charteris DG. Wong D. Khaw PT. Aylward GW. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001. 108(7):1179-83.
12. Jonas JB. Hayler JK. Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. British Journal of Ophthalmology. 2000; 84(9):1064-7.
13. Takahashi M. Refojo MF. Nakagawa M. Veloso A Jr. Leong FL. Antiproliferative effect of retinoic acid in 1% sodium hyaluronate in an animal model of PVR. Current Eye Research. 1997; 16(7):703-9.
top

Copyright ©2022. All rights reserved. Reproduction in whole or in part in any form or medium without expressed written permission of the Digital Journal of Ophthalmology is prohibited.